Development and validation of prognostic markers in sarcomas base on a multi-omics analysis

In sarcomas, the DNA copy number and DNA methylation exhibit genomic aberrations. Transcriptome imbalances play a driving role in the heterogeneous progression of sarcomas. However, it is still unclear whether abnormalities of DNA copy numbers are systematically related to epigenetic DNA methylation...

Full description

Saved in:
Bibliographic Details
Published inBMC medical genomics Vol. 14; no. 1; pp. 31 - 15
Main Authors Song, Yongchun, Yang, Kui, Sun, Tuanhe, Tang, Ruixiang
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 28.01.2021
BioMed Central
BMC
Subjects
Bioinformatics
Biomarkers
Biomarkers, Tumor - genetics
Cancer
Cluster analysis
CNV
Computational biology
Copy number
Deoxyribonucleic acid
DNA
DNA Copy Number Variations
DNA Methylation
Epigenesis, Genetic
Epigenetic inheritance
Epigenetics
Female
Gene expression
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
Genetic aspects
Genetic markers
Genomes
Genomic analysis
Genomics
Humans
Male
Medical prognosis
Methods
Methylation
Molecular modelling
Multiomics
Mutation
Neoantigens
Oncology, Experimental
Prognosis
Sarcoma
Sarcoma - genetics
Sarcoma - pathology
Sarcomas
Survival analysis
TCGA
Transcriptomes
South Korea
United States > US
China
Sarcomas
CNV
Methylation
Bioinformatics
TCGA
Online AccessGet full text

Cover

Abstract In sarcomas, the DNA copy number and DNA methylation exhibit genomic aberrations. Transcriptome imbalances play a driving role in the heterogeneous progression of sarcomas. However, it is still unclear whether abnormalities of DNA copy numbers are systematically related to epigenetic DNA methylation, thus, a comprehensive analysis of sarcoma occurrence and development from the perspective of epigenetic and genomics is required. RNASeq, copy number variation (CNV), methylation data, clinical follow-up information were obtained from The Cancer Genome Atlas (TCGA) and GEO database. The association between methylation and CNV was analyzed to further identify methylation-related genes (MET-Gs) and CNV abnormality-related genes (CNV-Gs). Subsequently DNA copy number, methylation, and gene expression data associated with the MET-Gs and CNV-Gs were integrated to determine molecular subtypes and clinical and molecular characteristics of molecular subtypes. Finally, key biomarkers were determined and validated in independent validation sets. A total of 5354 CNV-Gs and 4042 MET-Gs were screened and showed a high degree of consistency. Four molecular subtypes (iC1, iC2, iC3, and iC4) with different prognostic significances were identified by multiomics cluster analysis, specifically, iC2 had the worst prognosis and iC4 indicated an immune-enhancing state. Three potential prognostic markers (ENO1, ACVRL1 and APBB1IP) were determined after comparing the molecular characteristics of the four molecular subtypes. The expression of ENO1 gene was significantly correlated with CNV, and was noticeably higher in iC2 subtype with the worst prognosis than any other subtypes. The expressions of ACVRL1 and APBB1IP were negatively correlated with methylation, and were high-expressed in the iC4 subtype with the most favorable prognosis. In addition, the number of silent/nonsilent mutations and neoantigens in iC2 subtype were significantly more than those in iC1/iC3/iC4 subtype, and the same trend was also observed in CNV Gain/Loss. The current comprehensive analysis of genomic and epigenomic regulation provides new insights into multilayered pathobiology of sarcomas. Four molecular subtypes and three prognostic markers developed in this study improve the current understanding of the molecular mechanisms underlying sarcoma.
AbstractList Abstract Background In sarcomas, the DNA copy number and DNA methylation exhibit genomic aberrations. Transcriptome imbalances play a driving role in the heterogeneous progression of sarcomas. However, it is still unclear whether abnormalities of DNA copy numbers are systematically related to epigenetic DNA methylation, thus, a comprehensive analysis of sarcoma occurrence and development from the perspective of epigenetic and genomics is required. Methods RNASeq, copy number variation (CNV), methylation data, clinical follow-up information were obtained from The Cancer Genome Atlas (TCGA) and GEO database. The association between methylation and CNV was analyzed to further identify methylation-related genes (MET-Gs) and CNV abnormality-related genes (CNV-Gs). Subsequently DNA copy number, methylation, and gene expression data associated with the MET-Gs and CNV-Gs were integrated to determine molecular subtypes and clinical and molecular characteristics of molecular subtypes. Finally, key biomarkers were determined and validated in independent validation sets. Results A total of 5354 CNV-Gs and 4042 MET-Gs were screened and showed a high degree of consistency. Four molecular subtypes (iC1, iC2, iC3, and iC4) with different prognostic significances were identified by multiomics cluster analysis, specifically, iC2 had the worst prognosis and iC4 indicated an immune-enhancing state. Three potential prognostic markers (ENO1, ACVRL1 and APBB1IP) were determined after comparing the molecular characteristics of the four molecular subtypes. The expression of ENO1 gene was significantly correlated with CNV, and was noticeably higher in iC2 subtype with the worst prognosis than any other subtypes. The expressions of ACVRL1 and APBB1IP were negatively correlated with methylation, and were high-expressed in the iC4 subtype with the most favorable prognosis. In addition, the number of silent/nonsilent mutations and neoantigens in iC2 subtype were significantly more than those in iC1/iC3/iC4 subtype, and the same trend was also observed in CNV Gain/Loss. Conclusion The current comprehensive analysis of genomic and epigenomic regulation provides new insights into multilayered pathobiology of sarcomas. Four molecular subtypes and three prognostic markers developed in this study improve the current understanding of the molecular mechanisms underlying sarcoma.
In sarcomas, the DNA copy number and DNA methylation exhibit genomic aberrations. Transcriptome imbalances play a driving role in the heterogeneous progression of sarcomas. However, it is still unclear whether abnormalities of DNA copy numbers are systematically related to epigenetic DNA methylation, thus, a comprehensive analysis of sarcoma occurrence and development from the perspective of epigenetic and genomics is required. RNASeq, copy number variation (CNV), methylation data, clinical follow-up information were obtained from The Cancer Genome Atlas (TCGA) and GEO database. The association between methylation and CNV was analyzed to further identify methylation-related genes (MET-Gs) and CNV abnormality-related genes (CNV-Gs). Subsequently DNA copy number, methylation, and gene expression data associated with the MET-Gs and CNV-Gs were integrated to determine molecular subtypes and clinical and molecular characteristics of molecular subtypes. Finally, key biomarkers were determined and validated in independent validation sets. A total of 5354 CNV-Gs and 4042 MET-Gs were screened and showed a high degree of consistency. Four molecular subtypes (iC1, iC2, iC3, and iC4) with different prognostic significances were identified by multiomics cluster analysis, specifically, iC2 had the worst prognosis and iC4 indicated an immune-enhancing state. Three potential prognostic markers (ENO1, ACVRL1 and APBB1IP) were determined after comparing the molecular characteristics of the four molecular subtypes. The expression of ENO1 gene was significantly correlated with CNV, and was noticeably higher in iC2 subtype with the worst prognosis than any other subtypes. The expressions of ACVRL1 and APBB1IP were negatively correlated with methylation, and were high-expressed in the iC4 subtype with the most favorable prognosis. In addition, the number of silent/nonsilent mutations and neoantigens in iC2 subtype were significantly more than those in iC1/iC3/iC4 subtype, and the same trend was also observed in CNV Gain/Loss. The current comprehensive analysis of genomic and epigenomic regulation provides new insights into multilayered pathobiology of sarcomas. Four molecular subtypes and three prognostic markers developed in this study improve the current understanding of the molecular mechanisms underlying sarcoma.
In sarcomas, the DNA copy number and DNA methylation exhibit genomic aberrations. Transcriptome imbalances play a driving role in the heterogeneous progression of sarcomas. However, it is still unclear whether abnormalities of DNA copy numbers are systematically related to epigenetic DNA methylation, thus, a comprehensive analysis of sarcoma occurrence and development from the perspective of epigenetic and genomics is required. RNASeq, copy number variation (CNV), methylation data, clinical follow-up information were obtained from The Cancer Genome Atlas (TCGA) and GEO database. The association between methylation and CNV was analyzed to further identify methylation-related genes (MET-Gs) and CNV abnormality-related genes (CNV-Gs). Subsequently DNA copy number, methylation, and gene expression data associated with the MET-Gs and CNV-Gs were integrated to determine molecular subtypes and clinical and molecular characteristics of molecular subtypes. Finally, key biomarkers were determined and validated in independent validation sets. A total of 5354 CNV-Gs and 4042 MET-Gs were screened and showed a high degree of consistency. Four molecular subtypes (iC1, iC2, iC3, and iC4) with different prognostic significances were identified by multiomics cluster analysis, specifically, iC2 had the worst prognosis and iC4 indicated an immune-enhancing state. Three potential prognostic markers (ENO1, ACVRL1 and APBB1IP) were determined after comparing the molecular characteristics of the four molecular subtypes. The expression of ENO1 gene was significantly correlated with CNV, and was noticeably higher in iC2 subtype with the worst prognosis than any other subtypes. The expressions of ACVRL1 and APBB1IP were negatively correlated with methylation, and were high-expressed in the iC4 subtype with the most favorable prognosis. In addition, the number of silent/nonsilent mutations and neoantigens in iC2 subtype were significantly more than those in iC1/iC3/iC4 subtype, and the same trend was also observed in CNV Gain/Loss. The current comprehensive analysis of genomic and epigenomic regulation provides new insights into multilayered pathobiology of sarcomas. Four molecular subtypes and three prognostic markers developed in this study improve the current understanding of the molecular mechanisms underlying sarcoma.
In sarcomas, the DNA copy number and DNA methylation exhibit genomic aberrations. Transcriptome imbalances play a driving role in the heterogeneous progression of sarcomas. However, it is still unclear whether abnormalities of DNA copy numbers are systematically related to epigenetic DNA methylation, thus, a comprehensive analysis of sarcoma occurrence and development from the perspective of epigenetic and genomics is required.BACKGROUNDIn sarcomas, the DNA copy number and DNA methylation exhibit genomic aberrations. Transcriptome imbalances play a driving role in the heterogeneous progression of sarcomas. However, it is still unclear whether abnormalities of DNA copy numbers are systematically related to epigenetic DNA methylation, thus, a comprehensive analysis of sarcoma occurrence and development from the perspective of epigenetic and genomics is required.RNASeq, copy number variation (CNV), methylation data, clinical follow-up information were obtained from The Cancer Genome Atlas (TCGA) and GEO database. The association between methylation and CNV was analyzed to further identify methylation-related genes (MET-Gs) and CNV abnormality-related genes (CNV-Gs). Subsequently DNA copy number, methylation, and gene expression data associated with the MET-Gs and CNV-Gs were integrated to determine molecular subtypes and clinical and molecular characteristics of molecular subtypes. Finally, key biomarkers were determined and validated in independent validation sets.METHODSRNASeq, copy number variation (CNV), methylation data, clinical follow-up information were obtained from The Cancer Genome Atlas (TCGA) and GEO database. The association between methylation and CNV was analyzed to further identify methylation-related genes (MET-Gs) and CNV abnormality-related genes (CNV-Gs). Subsequently DNA copy number, methylation, and gene expression data associated with the MET-Gs and CNV-Gs were integrated to determine molecular subtypes and clinical and molecular characteristics of molecular subtypes. Finally, key biomarkers were determined and validated in independent validation sets.A total of 5354 CNV-Gs and 4042 MET-Gs were screened and showed a high degree of consistency. Four molecular subtypes (iC1, iC2, iC3, and iC4) with different prognostic significances were identified by multiomics cluster analysis, specifically, iC2 had the worst prognosis and iC4 indicated an immune-enhancing state. Three potential prognostic markers (ENO1, ACVRL1 and APBB1IP) were determined after comparing the molecular characteristics of the four molecular subtypes. The expression of ENO1 gene was significantly correlated with CNV, and was noticeably higher in iC2 subtype with the worst prognosis than any other subtypes. The expressions of ACVRL1 and APBB1IP were negatively correlated with methylation, and were high-expressed in the iC4 subtype with the most favorable prognosis. In addition, the number of silent/nonsilent mutations and neoantigens in iC2 subtype were significantly more than those in iC1/iC3/iC4 subtype, and the same trend was also observed in CNV Gain/Loss.RESULTSA total of 5354 CNV-Gs and 4042 MET-Gs were screened and showed a high degree of consistency. Four molecular subtypes (iC1, iC2, iC3, and iC4) with different prognostic significances were identified by multiomics cluster analysis, specifically, iC2 had the worst prognosis and iC4 indicated an immune-enhancing state. Three potential prognostic markers (ENO1, ACVRL1 and APBB1IP) were determined after comparing the molecular characteristics of the four molecular subtypes. The expression of ENO1 gene was significantly correlated with CNV, and was noticeably higher in iC2 subtype with the worst prognosis than any other subtypes. The expressions of ACVRL1 and APBB1IP were negatively correlated with methylation, and were high-expressed in the iC4 subtype with the most favorable prognosis. In addition, the number of silent/nonsilent mutations and neoantigens in iC2 subtype were significantly more than those in iC1/iC3/iC4 subtype, and the same trend was also observed in CNV Gain/Loss.The current comprehensive analysis of genomic and epigenomic regulation provides new insights into multilayered pathobiology of sarcomas. Four molecular subtypes and three prognostic markers developed in this study improve the current understanding of the molecular mechanisms underlying sarcoma.CONCLUSIONThe current comprehensive analysis of genomic and epigenomic regulation provides new insights into multilayered pathobiology of sarcomas. Four molecular subtypes and three prognostic markers developed in this study improve the current understanding of the molecular mechanisms underlying sarcoma.
Background In sarcomas, the DNA copy number and DNA methylation exhibit genomic aberrations. Transcriptome imbalances play a driving role in the heterogeneous progression of sarcomas. However, it is still unclear whether abnormalities of DNA copy numbers are systematically related to epigenetic DNA methylation, thus, a comprehensive analysis of sarcoma occurrence and development from the perspective of epigenetic and genomics is required. Methods RNASeq, copy number variation (CNV), methylation data, clinical follow-up information were obtained from The Cancer Genome Atlas (TCGA) and GEO database. The association between methylation and CNV was analyzed to further identify methylation-related genes (MET-Gs) and CNV abnormality-related genes (CNV-Gs). Subsequently DNA copy number, methylation, and gene expression data associated with the MET-Gs and CNV-Gs were integrated to determine molecular subtypes and clinical and molecular characteristics of molecular subtypes. Finally, key biomarkers were determined and validated in independent validation sets. Results A total of 5354 CNV-Gs and 4042 MET-Gs were screened and showed a high degree of consistency. Four molecular subtypes (iC1, iC2, iC3, and iC4) with different prognostic significances were identified by multiomics cluster analysis, specifically, iC2 had the worst prognosis and iC4 indicated an immune-enhancing state. Three potential prognostic markers (ENO1, ACVRL1 and APBB1IP) were determined after comparing the molecular characteristics of the four molecular subtypes. The expression of ENO1 gene was significantly correlated with CNV, and was noticeably higher in iC2 subtype with the worst prognosis than any other subtypes. The expressions of ACVRL1 and APBB1IP were negatively correlated with methylation, and were high-expressed in the iC4 subtype with the most favorable prognosis. In addition, the number of silent/nonsilent mutations and neoantigens in iC2 subtype were significantly more than those in iC1/iC3/iC4 subtype, and the same trend was also observed in CNV Gain/Loss. Conclusion The current comprehensive analysis of genomic and epigenomic regulation provides new insights into multilayered pathobiology of sarcomas. Four molecular subtypes and three prognostic markers developed in this study improve the current understanding of the molecular mechanisms underlying sarcoma.
Abstract Background In sarcomas, the DNA copy number and DNA methylation exhibit genomic aberrations. Transcriptome imbalances play a driving role in the heterogeneous progression of sarcomas. However, it is still unclear whether abnormalities of DNA copy numbers are systematically related to epigenetic DNA methylation, thus, a comprehensive analysis of sarcoma occurrence and development from the perspective of epigenetic and genomics is required. Methods RNASeq, copy number variation (CNV), methylation data, clinical follow-up information were obtained from The Cancer Genome Atlas (TCGA) and GEO database. The association between methylation and CNV was analyzed to further identify methylation-related genes (MET-Gs) and CNV abnormality-related genes (CNV-Gs). Subsequently DNA copy number, methylation, and gene expression data associated with the MET-Gs and CNV-Gs were integrated to determine molecular subtypes and clinical and molecular characteristics of molecular subtypes. Finally, key biomarkers were determined and validated in independent validation sets. Results A total of 5354 CNV-Gs and 4042 MET-Gs were screened and showed a high degree of consistency. Four molecular subtypes (iC1, iC2, iC3, and iC4) with different prognostic significances were identified by multiomics cluster analysis, specifically, iC2 had the worst prognosis and iC4 indicated an immune-enhancing state. Three potential prognostic markers (ENO1, ACVRL1 and APBB1IP) were determined after comparing the molecular characteristics of the four molecular subtypes. The expression of ENO1 gene was significantly correlated with CNV, and was noticeably higher in iC2 subtype with the worst prognosis than any other subtypes. The expressions of ACVRL1 and APBB1IP were negatively correlated with methylation, and were high-expressed in the iC4 subtype with the most favorable prognosis. In addition, the number of silent/nonsilent mutations and neoantigens in iC2 subtype were significantly more than those in iC1/iC3/iC4 subtype, and the same trend was also observed in CNV Gain/Loss. Conclusion The current comprehensive analysis of genomic and epigenomic regulation provides new insights into multilayered pathobiology of sarcomas. Four molecular subtypes and three prognostic markers developed in this study improve the current understanding of the molecular mechanisms underlying sarcoma.
Background In sarcomas, the DNA copy number and DNA methylation exhibit genomic aberrations. Transcriptome imbalances play a driving role in the heterogeneous progression of sarcomas. However, it is still unclear whether abnormalities of DNA copy numbers are systematically related to epigenetic DNA methylation, thus, a comprehensive analysis of sarcoma occurrence and development from the perspective of epigenetic and genomics is required. Methods RNASeq, copy number variation (CNV), methylation data, clinical follow-up information were obtained from The Cancer Genome Atlas (TCGA) and GEO database. The association between methylation and CNV was analyzed to further identify methylation-related genes (MET-Gs) and CNV abnormality-related genes (CNV-Gs). Subsequently DNA copy number, methylation, and gene expression data associated with the MET-Gs and CNV-Gs were integrated to determine molecular subtypes and clinical and molecular characteristics of molecular subtypes. Finally, key biomarkers were determined and validated in independent validation sets. Results A total of 5354 CNV-Gs and 4042 MET-Gs were screened and showed a high degree of consistency. Four molecular subtypes (iC1, iC2, iC3, and iC4) with different prognostic significances were identified by multiomics cluster analysis, specifically, iC2 had the worst prognosis and iC4 indicated an immune-enhancing state. Three potential prognostic markers (ENO1, ACVRL1 and APBB1IP) were determined after comparing the molecular characteristics of the four molecular subtypes. The expression of ENO1 gene was significantly correlated with CNV, and was noticeably higher in iC2 subtype with the worst prognosis than any other subtypes. The expressions of ACVRL1 and APBB1IP were negatively correlated with methylation, and were high-expressed in the iC4 subtype with the most favorable prognosis. In addition, the number of silent/nonsilent mutations and neoantigens in iC2 subtype were significantly more than those in iC1/iC3/iC4 subtype, and the same trend was also observed in CNV Gain/Loss. Conclusion The current comprehensive analysis of genomic and epigenomic regulation provides new insights into multilayered pathobiology of sarcomas. Four molecular subtypes and three prognostic markers developed in this study improve the current understanding of the molecular mechanisms underlying sarcoma. Keywords: Bioinformatics, Sarcomas, CNV, Methylation, TCGA
ArticleNumber 31
Audience Academic
Author Tang, Ruixiang
Yang, Kui
Sun, Tuanhe
Song, Yongchun
Author_xml – sequence: 1
  givenname: Yongchun
  surname: Song
  fullname: Song, Yongchun
  organization: Department of Oncology Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, 277 West Yanta Road, Xi'an, 710061, Shaanxi, China
– sequence: 2
  givenname: Kui
  surname: Yang
  fullname: Yang, Kui
  organization: Department of General Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, China
– sequence: 3
  givenname: Tuanhe
  surname: Sun
  fullname: Sun, Tuanhe
  organization: Department of Oncology Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, 277 West Yanta Road, Xi'an, 710061, Shaanxi, China
– sequence: 4
  givenname: Ruixiang
  surname: Tang
  fullname: Tang, Ruixiang
  email: caitang0613@xjtu.edu.cn
  organization: Department of Oncology Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, 277 West Yanta Road, Xi'an, 710061, Shaanxi, China. caitang0613@xjtu.edu.cn
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33509178$$D View this record in MEDLINE/PubMed
BookMark eNptkktv1DAUhSNURB_wB1igSGzoIsWO3xukqrxGqoTEY8XCuvFj8JDEUzsZ0X9fT6eMOgh5Yev6u8f28TmtjsY4uqp6idEFxpK_zbhVLWpQixuEpOANfVKdYMFYI4WiR4_Wx9VpziuEOGIKP6uOCWFIYSFPqp_v3cb1cT24caphtPUG-mBhCnGso6_XKS7HmKdg6gHSb5dyHcY6QzJxgFx3kF1dSKiHuZ9CE4dgcpGB_jaH_Lx66qHP7sXDfFb9-Pjh-9Xn5vrLp8XV5XVjmBJTA94zxYQ1nhKPOoIQwkgQ3lnrMeWiFRy4M6qzhhvLSOelBehaYNIpghk5qxY7XRthpdcplKve6ghB3xdiWmpI5Qm908KD6ZCVXjBLCcaKADGC8Q5k2xELRevdTms9d4OzptiSoD8QPdwZwy-9jBstJMUK0SLw5kEgxZvZ5UkPIRvX9zC6OGfdUkkkJhyjgr7-B13FORXztpRCqmVbeE8toTwgjD6Wc81WVF9yhijDlIpCXfyHKsO68iclNz6U-kHD-UFDYSb3Z1rCnLNefPt6yLY71qSYc3J-7wdGehtFvYuiLlHU91HUWyNePXZy3_I3e-QOZdHapw
CitedBy_id crossref_primary_10_1302_0301_620X_104B9_BJJ_2022_0647
crossref_primary_10_3390_ijms231911430
crossref_primary_10_1371_journal_pone_0272093
crossref_primary_10_3389_fonc_2022_946022
Cites_doi 10.1109/TCBB.2014.2328342
10.1109/TBME.2019.2915762
10.1016/j.cell.2011.02.013
10.1002/hed.24406
10.1038/nature07943
10.1186/s12943-018-0930-x
10.1093/nar/gky1226
10.18632/aging.102047
10.1016/S0140-6736(12)60651-5
10.3322/caac.21338
10.1371/journal.pone.0035236
10.1126/science.1129139
10.1016/j.cell.2017.10.014
10.1186/s40880-016-0142-y
10.1074/jbc.M110.189811
10.1002/path.2491
10.1053/j.gastro.2017.06.066
10.1186/s13059-014-0550-8
10.3390/genes9120586
10.1200/JCO.2015.63.0970
10.1111/j.1538-7836.2010.03860.x
10.3322/caac.21442
10.1186/s13059-016-1028-7
10.6004/jnccn.2014.0053
10.18632/oncotarget.10054
10.1093/carcin/bgu043
10.1056/NEJMra072067
10.1097/MD.0000000000001631
10.1158/1535-7163.MCT-09-0650
10.1002/ijc.31903
10.1084/jem.20091309
10.1038/nature20805
10.1182/blood-2011-01-330142
10.1038/nature13176
10.1007/s00535-016-1265-2
10.1158/1078-0432.CCR-17-0252
10.1038/s41467-017-00991-w
10.1111/j.1467-2995.2010.00536.x
10.1016/S0959-8049(02)00480-X
10.1038/onc.2015.209
10.1002/hep.22033
10.1371/journal.pone.0106801
ContentType Journal Article
Copyright COPYRIGHT 2021 BioMed Central Ltd.
2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2021
Copyright_xml – notice: COPYRIGHT 2021 BioMed Central Ltd.
– notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2021
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
ISR
3V.
7X7
7XB
88E
8AO
8FD
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M7P
P64
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
RC3
7X8
5PM
DOA
DOI 10.1186/s12920-021-00876-4
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Gale In Context: Science
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Technology Research Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central Korea
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
Health & Medical Collection (Alumni Edition)
Medical Database
Biological Science Database
Biotechnology and BioEngineering Abstracts
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
Genetics Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Publicly Available Content Database
ProQuest Central Student
Technology Research Database
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
Genetics Abstracts
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Medical Library (Alumni)
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Engineering Research Database
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList

MEDLINE
MEDLINE - Academic
Publicly Available Content Database
CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1755-8794
EndPage 15
ExternalDocumentID oai_doaj_org_article_7facb0d8f75d431193a3c756ba82b3da
A650451447
10_1186_s12920_021_00876_4
33509178
Genre Journal Article
GeographicLocations South Korea
United States--US
China
GeographicLocations_xml – name: South Korea
– name: China
– name: United States--US
GrantInformation_xml – fundername: National Natural Science Foundation of China
  grantid: 81702281
– fundername: ;
  grantid: 81702281
GroupedDBID ---
-A0
0R~
23N
2WC
3V.
53G
5GY
5VS
6J9
7X7
88E
8AO
8FE
8FH
8FI
8FJ
AAFWJ
AAJSJ
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACMJI
ACPRK
ACRMQ
ADBBV
ADINQ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BBNVY
BCNDV
BENPR
BFQNJ
BHPHI
BMC
BPHCQ
BVXVI
C24
C6C
CCPQU
CGR
CS3
CUY
CVF
DIK
DU5
E3Z
EBD
EBLON
EBS
ECM
EIF
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HMCUK
HYE
IAO
IHR
INH
INR
ISR
ITC
KQ8
LK8
M1P
M48
M7P
M~E
NPM
O5R
O5S
OK1
P2P
PGMZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
SV3
TR2
TUS
UKHRP
W2D
~8M
AAYXX
CITATION
AFGXO
ABVAZ
AFNRJ
7XB
8FD
8FK
AZQEC
DWQXO
FR3
GNUQQ
K9.
P64
PQEST
PQUKI
PRINS
RC3
7X8
5PM
ID FETCH-LOGICAL-c597t-aff5957dcf43f0b300010736bddf1467276a6ec9bdc6cd53bf8daab2a58e93153
IEDL.DBID RPM
ISSN 1755-8794
IngestDate Tue Oct 22 15:09:52 EDT 2024
Tue Sep 17 21:03:49 EDT 2024
Sat Oct 26 04:34:44 EDT 2024
Thu Oct 10 17:54:02 EDT 2024
Fri Feb 23 00:06:11 EST 2024
Fri Feb 02 03:59:02 EST 2024
Thu Aug 01 20:25:41 EDT 2024
Thu Sep 12 18:02:26 EDT 2024
Sat Nov 02 12:29:12 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Sarcomas
CNV
Methylation
Bioinformatics
TCGA
Language English
License Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c597t-aff5957dcf43f0b300010736bddf1467276a6ec9bdc6cd53bf8daab2a58e93153
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841904/
PMID 33509178
PQID 2490925248
PQPubID 55237
PageCount 15
ParticipantIDs doaj_primary_oai_doaj_org_article_7facb0d8f75d431193a3c756ba82b3da
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7841904
proquest_miscellaneous_2483813610
proquest_journals_2490925248
gale_infotracmisc_A650451447
gale_infotracacademiconefile_A650451447
gale_incontextgauss_ISR_A650451447
crossref_primary_10_1186_s12920_021_00876_4
pubmed_primary_33509178
PublicationCentury 2000
PublicationDate 2021-01-28
PublicationDateYYYYMMDD 2021-01-28
PublicationDate_xml – month: 01
  year: 2021
  text: 2021-01-28
  day: 28
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle BMC medical genomics
PublicationTitleAlternate BMC Med Genomics
PublicationYear 2021
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References N Nguyen (876_CR36) 2016; 38
Y Chen (876_CR15) 2019; 18
MR Stratton (876_CR29) 2009; 458
AJ Lazar (876_CR26) 2017; 171
D Mitchell (876_CR44) 2010; 9
P Hernandez-Varas (876_CR47) 2011; 286
876_CR10
L Hu (876_CR13) 2015; 5
DC Lin (876_CR16) 2018; 154
AR Mair (876_CR34) 2010; 37
B Li (876_CR24) 2016; 17
C Ye (876_CR22) 2019; 67
D Hanahan (876_CR28) 2011; 144
M Zheng (876_CR19) 2019; 11
N Rappoport (876_CR6) 2019; 47
Y Zhang (876_CR41) 2010; 13
JY Blay (876_CR4) 2003; 39
YB Chen (876_CR14) 2016; 35
W Chen (876_CR3) 2016; 66
Y Sun (876_CR12) 2014; 35
M von Mehren (876_CR1) 2014; 12
SI Cunha (876_CR45) 2011; 117
M Esteller (876_CR33) 2008; 358
WL Chang (876_CR17) 2017; 52
MK Asiedu (876_CR8) 2018; 24
CA Eads (876_CR9) 2001; 61
C Schlaeger (876_CR30) 2008; 47
A Mirzal (876_CR20) 2014; 11
M Esteller (876_CR32) 2001; 61
MI Love (876_CR25) 2014; 15
Y Song (876_CR11) 2014; 509
Y Chochi (876_CR31) 2009; 217
E Brambilla (876_CR37) 2016; 34
K Liu (876_CR39) 2015; 94
N Yu (876_CR21) 2018; 9
MF Orth (876_CR27) 2019; 144
R Shen (876_CR23) 2012; 7
S Dupuis-Girod (876_CR43) 2010; 8
RL Siegel (876_CR2) 2018; 68
L Liang (876_CR7) 2016; 35
J Galon (876_CR38) 2006; 313
SI Cunha (876_CR46) 2010; 207
HG Woo (876_CR18) 2017; 8
T Tian (876_CR35) 2016; 7
YS Chang (876_CR40) 2003; 9
A Takahashi (876_CR42) 2014; 9
WT van der Graaf (876_CR5) 2012; 379
References_xml – volume: 11
  start-page: 1208
  issue: 6
  year: 2014
  ident: 876_CR20
  publication-title: IEEE/ACM Trans Comput Biol Bioinform
  doi: 10.1109/TCBB.2014.2328342
  contributor:
    fullname: A Mirzal
– volume: 67
  start-page: 482
  year: 2019
  ident: 876_CR22
  publication-title: IEEE Trans Biomed Eng
  doi: 10.1109/TBME.2019.2915762
  contributor:
    fullname: C Ye
– volume: 61
  start-page: 3225
  issue: 8
  year: 2001
  ident: 876_CR32
  publication-title: Can Res
  contributor:
    fullname: M Esteller
– volume: 144
  start-page: 646
  issue: 5
  year: 2011
  ident: 876_CR28
  publication-title: Cell
  doi: 10.1016/j.cell.2011.02.013
  contributor:
    fullname: D Hanahan
– volume: 38
  start-page: 1074
  issue: 7
  year: 2016
  ident: 876_CR36
  publication-title: Head Neck
  doi: 10.1002/hed.24406
  contributor:
    fullname: N Nguyen
– volume: 61
  start-page: 3410
  issue: 8
  year: 2001
  ident: 876_CR9
  publication-title: Cancer Res
  contributor:
    fullname: CA Eads
– volume: 458
  start-page: 719
  issue: 7239
  year: 2009
  ident: 876_CR29
  publication-title: Nature
  doi: 10.1038/nature07943
  contributor:
    fullname: MR Stratton
– volume: 18
  start-page: 1
  issue: 1
  year: 2019
  ident: 876_CR15
  publication-title: Mol Cancer
  doi: 10.1186/s12943-018-0930-x
  contributor:
    fullname: Y Chen
– volume: 47
  start-page: 1044
  issue: 2
  year: 2019
  ident: 876_CR6
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gky1226
  contributor:
    fullname: N Rappoport
– volume: 11
  start-page: 4198
  issue: 12
  year: 2019
  ident: 876_CR19
  publication-title: Aging (Albany NY)
  doi: 10.18632/aging.102047
  contributor:
    fullname: M Zheng
– volume: 379
  start-page: 1879
  issue: 9829
  year: 2012
  ident: 876_CR5
  publication-title: Lancet (London, England)
  doi: 10.1016/S0140-6736(12)60651-5
  contributor:
    fullname: WT van der Graaf
– volume: 66
  start-page: 115
  issue: 2
  year: 2016
  ident: 876_CR3
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21338
  contributor:
    fullname: W Chen
– volume: 7
  start-page: e35236
  issue: 4
  year: 2012
  ident: 876_CR23
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0035236
  contributor:
    fullname: R Shen
– volume: 313
  start-page: 1960
  issue: 5795
  year: 2006
  ident: 876_CR38
  publication-title: Science
  doi: 10.1126/science.1129139
  contributor:
    fullname: J Galon
– volume: 171
  start-page: 950
  issue: 4
  year: 2017
  ident: 876_CR26
  publication-title: Cell
  doi: 10.1016/j.cell.2017.10.014
  contributor:
    fullname: AJ Lazar
– volume: 35
  start-page: 76
  issue: 1
  year: 2016
  ident: 876_CR14
  publication-title: Chin J Cancer
  doi: 10.1186/s40880-016-0142-y
  contributor:
    fullname: YB Chen
– volume: 286
  start-page: 18492
  issue: 21
  year: 2011
  ident: 876_CR47
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M110.189811
  contributor:
    fullname: P Hernandez-Varas
– volume: 217
  start-page: 677
  issue: 5
  year: 2009
  ident: 876_CR31
  publication-title: J Pathol
  doi: 10.1002/path.2491
  contributor:
    fullname: Y Chochi
– volume: 154
  start-page: 374
  issue: 2
  year: 2018
  ident: 876_CR16
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2017.06.066
  contributor:
    fullname: DC Lin
– volume: 15
  start-page: 550
  issue: 12
  year: 2014
  ident: 876_CR25
  publication-title: Genome Biol
  doi: 10.1186/s13059-014-0550-8
  contributor:
    fullname: MI Love
– volume: 9
  start-page: 586
  issue: 12
  year: 2018
  ident: 876_CR21
  publication-title: Genes (Basel)
  doi: 10.3390/genes9120586
  contributor:
    fullname: N Yu
– volume: 34
  start-page: 1223
  issue: 11
  year: 2016
  ident: 876_CR37
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2015.63.0970
  contributor:
    fullname: E Brambilla
– volume: 8
  start-page: 1447
  issue: 7
  year: 2010
  ident: 876_CR43
  publication-title: J Thromb Haemost
  doi: 10.1111/j.1538-7836.2010.03860.x
  contributor:
    fullname: S Dupuis-Girod
– volume: 68
  start-page: 7
  issue: 1
  year: 2018
  ident: 876_CR2
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21442
  contributor:
    fullname: RL Siegel
– volume: 17
  start-page: 174
  issue: 1
  year: 2016
  ident: 876_CR24
  publication-title: Genome Biol
  doi: 10.1186/s13059-016-1028-7
  contributor:
    fullname: B Li
– volume: 12
  start-page: 473
  issue: 4
  year: 2014
  ident: 876_CR1
  publication-title: J Natl Compr Cancer Netw
  doi: 10.6004/jnccn.2014.0053
  contributor:
    fullname: M von Mehren
– volume: 7
  start-page: 44395
  issue: 28
  year: 2016
  ident: 876_CR35
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.10054
  contributor:
    fullname: T Tian
– volume: 35
  start-page: 1941
  issue: 9
  year: 2014
  ident: 876_CR12
  publication-title: Carcinogenesis
  doi: 10.1093/carcin/bgu043
  contributor:
    fullname: Y Sun
– volume: 358
  start-page: 1148
  issue: 11
  year: 2008
  ident: 876_CR33
  publication-title: N Engl J Med
  doi: 10.1056/NEJMra072067
  contributor:
    fullname: M Esteller
– volume: 94
  start-page: e1631
  issue: 39
  year: 2015
  ident: 876_CR39
  publication-title: Medicine (Baltimore)
  doi: 10.1097/MD.0000000000001631
  contributor:
    fullname: K Liu
– volume: 9
  start-page: 379
  issue: 2
  year: 2010
  ident: 876_CR44
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-09-0650
  contributor:
    fullname: D Mitchell
– volume: 144
  start-page: 859
  issue: 4
  year: 2019
  ident: 876_CR27
  publication-title: Int J Cancer
  doi: 10.1002/ijc.31903
  contributor:
    fullname: MF Orth
– volume: 207
  start-page: 85
  issue: 1
  year: 2010
  ident: 876_CR46
  publication-title: J Exp Med
  doi: 10.1084/jem.20091309
  contributor:
    fullname: SI Cunha
– volume: 5
  start-page: 3056
  issue: 10
  year: 2015
  ident: 876_CR13
  publication-title: Am J Cancer Res
  contributor:
    fullname: L Hu
– ident: 876_CR10
  doi: 10.1038/nature20805
– volume: 117
  start-page: 6999
  issue: 26
  year: 2011
  ident: 876_CR45
  publication-title: Blood
  doi: 10.1182/blood-2011-01-330142
  contributor:
    fullname: SI Cunha
– volume: 509
  start-page: 91
  issue: 7498
  year: 2014
  ident: 876_CR11
  publication-title: Nature
  doi: 10.1038/nature13176
  contributor:
    fullname: Y Song
– volume: 52
  start-page: 705
  issue: 6
  year: 2017
  ident: 876_CR17
  publication-title: J Gastroenterol
  doi: 10.1007/s00535-016-1265-2
  contributor:
    fullname: WL Chang
– volume: 24
  start-page: 1691
  issue: 7
  year: 2018
  ident: 876_CR8
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-17-0252
  contributor:
    fullname: MK Asiedu
– volume: 8
  start-page: 839
  issue: 1
  year: 2017
  ident: 876_CR18
  publication-title: Nat Commun
  doi: 10.1038/s41467-017-00991-w
  contributor:
    fullname: HG Woo
– volume: 13
  start-page: 1089
  issue: 12
  year: 2010
  ident: 876_CR41
  publication-title: Chin J Lung Cancer
  contributor:
    fullname: Y Zhang
– volume: 37
  start-page: 337
  issue: 4
  year: 2010
  ident: 876_CR34
  publication-title: Vet Anaesth Analg
  doi: 10.1111/j.1467-2995.2010.00536.x
  contributor:
    fullname: AR Mair
– volume: 39
  start-page: 64
  issue: 1
  year: 2003
  ident: 876_CR4
  publication-title: Eur J Cancer (Oxford, England)
  doi: 10.1016/S0959-8049(02)00480-X
  contributor:
    fullname: JY Blay
– volume: 9
  start-page: 3641
  issue: 10 Pt 1
  year: 2003
  ident: 876_CR40
  publication-title: Clinical Cancer Res
  contributor:
    fullname: YS Chang
– volume: 35
  start-page: 1475
  issue: 12
  year: 2016
  ident: 876_CR7
  publication-title: Oncogene
  doi: 10.1038/onc.2015.209
  contributor:
    fullname: L Liang
– volume: 47
  start-page: 511
  issue: 2
  year: 2008
  ident: 876_CR30
  publication-title: Hepatology (Baltimore, MD)
  doi: 10.1002/hep.22033
  contributor:
    fullname: C Schlaeger
– volume: 9
  start-page: e106801
  issue: 9
  year: 2014
  ident: 876_CR42
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0106801
  contributor:
    fullname: A Takahashi
SSID ssj0060591
Score 2.3091798
Snippet In sarcomas, the DNA copy number and DNA methylation exhibit genomic aberrations. Transcriptome imbalances play a driving role in the heterogeneous progression...
Abstract Background In sarcomas, the DNA copy number and DNA methylation exhibit genomic aberrations. Transcriptome imbalances play a driving role in the...
Background In sarcomas, the DNA copy number and DNA methylation exhibit genomic aberrations. Transcriptome imbalances play a driving role in the heterogeneous...
Abstract Background In sarcomas, the DNA copy number and DNA methylation exhibit genomic aberrations. Transcriptome imbalances play a driving role in the...
SourceID doaj
pubmedcentral
proquest
gale
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 31
SubjectTerms Bioinformatics
Biomarkers
Biomarkers, Tumor - genetics
Cancer
Cluster analysis
CNV
Computational biology
Copy number
Deoxyribonucleic acid
DNA
DNA Copy Number Variations
DNA Methylation
Epigenesis, Genetic
Epigenetic inheritance
Epigenetics
Female
Gene expression
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
Genetic aspects
Genetic markers
Genomes
Genomic analysis
Genomics
Humans
Male
Medical prognosis
Methods
Methylation
Molecular modelling
Multiomics
Mutation
Neoantigens
Oncology, Experimental
Prognosis
Sarcoma
Sarcoma - genetics
Sarcoma - pathology
Sarcomas
Survival analysis
TCGA
Transcriptomes
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gLAsojUJCLkDggq4nfORbUqkUqB6BSJQ6WHzHsoQlqdv8_M3F2tREHLlzXk2g9D89n5fNnQt6pLipoE5oBGA5MNiGzEAzkctRdG5Sok8LTyFdf9MW1_Hyjbvau-kJOWJEHLo47MdnHUCebjUrQ7ABveBGN0sFbHkQq0Khut5upsgYDRm-b7REZq0_GBi9lYkhHmDTYmFy0oUmt_-81ea8pLQmTex3o_BF5OENHelr-8mNyr-ufkPtX88fxQ_JjjwBEfZ8oJNGqXJlEh0yRidUPKMtMb5GTczfSVU9HSHSkCFFsZxQsPZ04hgxPK4_wmqJZ8pRcn599_3TB5rsTWIQtwpr5nFWrTIpZilwHgVgOqlmHlDIujtxor7vYhhR1TEqEbJP3gXtlu1bAMviMHPRD370gNHtrPTitETZL7XkwTeLeA66CxSE1tiIftq50v4tEhpu2Fla74ngHjneT452syEf09s4S5a2nHyDobg66-1fQK_IWY-VQwKJHhsxPvxlHd_ntqzsFyCkBBUpTkfezUR4gatHPBw5gVqh5tbA8WlhChcXl8DYl3Fzho4Nta91yxSXM_3g3jE8ia63vhg3aWABEAhBqRZ6XDNrNWwiEagaeNovcWjhmOdKvfk363_ipuK3ly__hyVfkAZ_KomHcHpGD9d2mew0wax3eTBX1B0b3JWM
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZgKyEuiDeBggxC4oCsJvEjzgm1qFVBaoUKlSpxsPyI2z2QlM3u_2cmcZaNkLjGkygZz-Nz_HmGkPey8RLShGIAhh0ThYvMuQps2aumdpLnQeJp5LNzdXopvl7Jq_TDrU-0yikmDoE6dB7_kR_AMiGvS1kK_en2N8OuUbi7mlpo3CV7JawU8gXZOzo-_3YxxWLA6nUxHZXR6qAvsDkTQ1rCUIuNiVk6Gqr2_xubd5LTnDi5k4lOHpIHCULSw3HOH5E7TfuY3DtLm-RPyM8dIhC1baBgTMuxdRLtIkVGVttheWb6C7k5q54uW9qDwSNViGJaoyBp6cA1ZHhquYfHjLVLnpLLk-Mfn09Z6qHAPCwV1szGKGtZBR8Fj7njiOnAq5ULIWKQLCtlVeNrF7zyQXIXdbDWlVbqpuYQDp-RRdu1zQtCo9XagtIKrqNQtnRVEUprAV9BkAiFzsjHSZXmdiyVYYYlhlZmVLwBxZtB8UZk5Ai1vZXEMtfDhW51bZLXmCpa7_KgYyUDIB0Am5b7Sipndel4sBl5h3NlsJBFi0yZa7vpe_Pl-4U5BOgpAA2KKiMfklDsYNa8TQcP4Kuw9tVMcn8mCZ7m58OTSZjk6b35a5cZebsdxjuRvdY23QZlNAAjDkg1I89HC9p-N-cI2Sq4u5rZ1kwx85F2eTPUAcct4zoXL___Wq_I_XIw-IKVep8s1qtN8xqA1Nq9Sd7yB7nkHXk
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA_nCeLL4bfVU6IIPki1bT77IHKKxymcD-rCgQ8hH825oO253QX9751J22WLh6_NpDTTmcxvyC8zhDwTjRcQJmQOYNjlvHQxd06BLXvZ1E6wIgi8jXz6SZ4s-MczcbZHpnZHowL7S1M77Ce1WP14-fvXnzfg8K-Tw2v5qi-x5VKOZINUYS3nV8jVikOmjlQ-vj1VAORel9PFmUvnzYJTquH_7069E6rmNMqduHR8gxyMgJIeDRZwk-w17S1y7XQ8Mr9Nvu3QgqhtAwXTWg6NlGgXKfKz2g6LNdOfyNRZ9XTZ0h7MH4lDFIMcBUlLE_MwxzvMPbxmqGRyhyyO3399d5KPHRVyD4nDOrcxilqo4CNnsXAMER74uHQhRNwyKyWtbHztgpc-COaiDta6ygrd1Aw2x7tkv-3a5j6h0WptQWkl05FLWzlVhspaQFuwZYRSZ-TFpEpzMRTOMCnh0NIMijegeJMUb3hG3qK2t5JY9Do96FbnZvQho6L1rgg6KhEA9wD0tMwrIZ3VlWPBZuQp_iuDZS1a5M2c203fmw9fPpsjAKIcsCFXGXk-CsUO_pq34zUEWBVWwppJHs4kwe_8fHgyCTOZrYFktqgrUXFY_5PtMM5ELlvbdBuU0QCTGODWjNwbLGi7bsYQwCmYrWa2NVPMfKRdfk9VwfEAuS74g_9_1kNyvUoGX-aVPiT769WmeQSwau0eJ1_5C-ctH0I
  priority: 102
  providerName: Scholars Portal
Title Development and validation of prognostic markers in sarcomas base on a multi-omics analysis
URI https://www.ncbi.nlm.nih.gov/pubmed/33509178
https://www.proquest.com/docview/2490925248
https://www.proquest.com/docview/2483813610
https://pubmed.ncbi.nlm.nih.gov/PMC7841904
https://doaj.org/article/7facb0d8f75d431193a3c756ba82b3da
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBdtB2MvY99z1wVtDPYw3MSWJcuPaWnpAimlXSGwB6EPqwssdomT_793sh1i9raXGKKziXR3up_i390R8o2XlkOYEDGAYRNnifGxMTnYshVlYTibOI7ZyPNrcXWfzRZ8cUB4nwsTSPvWLE-rv6vTavkncCsfV3bc88TGN_NzfFdWTLLxITkEA-2P6O32C_C8SPrsGCnGTYL9mGJkIoTyazF24mEM4yS2VtsLRqFm_787815oGtIm9-LQ5SvysgOQdNr-0NfkoKzekOfz7hX5W_J7jwZEdeUomNKybZxEa0-Rj1XVWJyZrpCZs27osqINmDsShSgGNQqSmgamYYw5yw08pq1c8o7cX178Or-Kuw4KsYWDwibW3vOC5876jPmJYYjowKeFcc7jFpnmQovSFsZZYR1nxkuntUk1l2XBYDN8T46quio_Euq1lBrWL2HSZ0KnJk9cqjWgK9giXCIj8qNfSvXYFspQ4YAhhWp1oEAHKuhAZRE5w9XeSWKR6_BFvX5QnapV7rU1Eyd9zh3gHICamtmcC6NlapjTEfmKulJYxqJCnsyD3jaN-nl3q6YAPDPAglkeke-dkK9Ba1Z3aQcwK6x8NZA8GUiCn9nhcG8SqvPzRsHhdVKkPM1g_l92w3gncteqst6ijARYxACnRuRDa0G7efeGGJF8YFuDhRmOgFOEKuCdExz_952fyIs0uEUSp_KEHG3W2_IzIKyNGYFfLfIReTadzu5mcD27uL65HYX_K-BznslR8Lknlfsq7g
link.rule.ids 230,315,730,783,787,867,888,2109,2228,12068,21400,24330,27936,27937,31731,31732,33756,33757,43322,43817,53804,53806
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSMAF8SwpBQxC4oCsbuJnTqggqi10e4BWWomD5Udc9kDSbnb_PzNJdtkIiWs8iZLxPD7Hn2cIeSerICFNKAZg2DOR-8S812DLQVWll3wSJZ5Gnp2r6aX4Opfz4YdbO9AqNzGxC9SxCfiP_AiWCZOykIUwH69vGHaNwt3VoYXGbXIH63BhBwM93y64AKmX-eagjFFHbY6tmRiSErpKbEyMklFXs__fyLyTmsa0yZ08dPKQPBgAJD3uZ_wRuVXVj8nd2bBF_oT83KEBUVdHCqa06Bsn0SZR5GPVDRZnpr-RmbNs6aKmLZg7EoUoJjUKko52TEOGZ5ZbeExfueQpuTz5cvF5yoYOCizAQmHFXEqylDqGJHiaeI6IDnxa-RgThshCK6eqUPoYVIiS-2Sic75w0lQlh2D4jOzVTV09JzQ5YxwoLecmCeUKr_NYOAfoCkJEzE1GPmxUaa_7Qhm2W2AYZXvFW1C87RRvRUY-oba3kljkurvQLK_s4DNWJxf8JJqkZQScA1DT8aCl8s4UnkeXkbc4VxbLWNTIk7ly67a1pz--22MAngKwoNAZeT8IpQZmLbjh2AF8FVa-GkkejiTBz8J4eGMSdvDz1v61yoy82Q7jnchdq6tmjTIGYBEHnJqR_d6Ctt_NOQI2DXfrkW2NFDMeqRe_uirguGFcTsTB_1_rNbk3vZid2bPT828vyP2iM_6cFeaQ7K2W6-olQKqVf9X5zR-GNh8E
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELZgkVZceD8CCxiExAGleTh2nOOyUO0CXa2AlVZwsPyIlwqaVE174dczk0fVwG2v9aSSM9_MfFY-zxDympeWQ5kQIZBhE2aJ8aExOWDZirIwnMWO423k2ak4Ps8-XvCLnVFfrWjfmvmk-r2YVPOfrbZyubDRoBOLzmZH-K2siLNo6Xx0ndyAmI3FcFDvkjCQ9CIZ7shIETUJTmUKUY_QNmELcR4PY1gtccDaTklqO_f_n593CtRYPLlTjaa3yfdhH50I5ddkszYT--efFo9X2ugdcqvnqPSwM7lLrpXVPbI_67_C3yc_dpRGVFeOAlrn3WwmWnuKkq-qxv7PdIHin1VD5xVtIKJQi0SxblKw1LQVM4Z4LbqBv-maozwg59MP346Ow35IQ2jhLLIOtfe84LmzPmM-NgxJI6QNYZzzmIXTXGhR2sI4K6zjzHjptDap5rIsGOTbh2SvqqvyMaFeS6nBOQmTPhM6NXniUq2BwEEWcokMyNvBT2rZ9eJQ7RlGCtU5WIGDVetglQXkHbpya4l9tNsf6tWl6l-yyr22JnbS59wBlQI2q5nNuTBapoY5HZBXCASFnTIqlOJc6k3TqJOvX9QhcNsM6GaWB-RNb-RrgITV_c0G2BU21xpZHowsIZTteHnAm-pTSaPgfBwXKU8z2P_L7TI-ifK4qqw3aCOBeTGgwgF51MFzu-8B5QHJR8AdvZjxCsCxbTTew-_JlZ98QfbP3k_V55PTT0_JzbQNvyRM5QHZW6825TPgc2vzvI3cvxyCSYk
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Development+and+validation+of+prognostic+markers+in+sarcomas+base+on+a+multi-omics+analysis&rft.jtitle=BMC+medical+genomics&rft.au=Song%2C+Yongchun&rft.au=Yang%2C+Kui&rft.au=Sun%2C+Tuanhe&rft.au=Tang%2C+Ruixiang&rft.date=2021-01-28&rft.pub=BioMed+Central&rft.eissn=1755-8794&rft.volume=14&rft.spage=1&rft_id=info:doi/10.1186%2Fs12920-021-00876-4
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1755-8794&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1755-8794&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1755-8794&client=summon